US FDA Approval Expands Arexvy Prescription Demographics to 50-59 Age Bracket

US FDA Approves Arexvy for 50-59 Age Group

The recent approval by the US FDA to allow Arexvy's prescription for patients aged between 50 and 59 marks a pivotal moment for GSK.

Key Highlights:

• Expansion: Arexvy's approval for a wider age group signifies increased market potential.
• Opportunities: GSK stands to benefit from the extended prescription demographic.
• Impact: This move is expected to positively influence GSK's growth trajectory in the future.